Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
9.45M
-
Shares change
-
-386K
-
Total reported value, excl. options
-
$11.9M
-
Value change
-
-$696K
-
Put/Call ratio
-
0.25
-
Number of buys
-
23
-
Number of sells
-
-31
-
Price
-
$1.26
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q1 2024
77 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q1 2024.
Protalix BioTherapeutics, Inc. - COM (PLX) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.45M shares
.
Largest 10 shareholders include BlackRock Inc. (3.31M shares), STATE STREET CORP (827K shares), RENAISSANCE TECHNOLOGIES LLC (825K shares), GEODE CAPITAL MANAGEMENT, LLC (754K shares), GSA CAPITAL PARTNERS LLP (494K shares), NORTHERN TRUST CORP (458K shares), VANGUARD GROUP INC (330K shares), Nuveen Asset Management, LLC (272K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (184K shares), and Bank of New York Mellon Corp (173K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.